SUZHOU, China, May 29, 2023
/PRNewswire/ -- On May 26, 2023, the
"CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma
Anniversary Celebration," meticulously planned by Hillgene
Biopharma and Biovalley, was successfully held at the DoubleTree by
Hilton in Wuzhong District, Suzhou. The event was well-attended,
with regulatory experts, scientific researchers from academic
associations, professional investors from capital institutions, and
industry-leading corporate leaders gathered to discuss the future
of cell therapy.
Opening Address
Zhang Dan, the co-founder and
co-chairman from Jiangsu Hillgene Biopharma Co., Ltd., served as
the host and gave a speech at the opening ceremony of the
conference. "This is the 1st summit of CELL WORLD, and Hillgene
Biopharma will host this summit in the long term. Each event will
focus on a common concern, addressing the challenges faced by the
industry and unmet clinical needs, offering a stage-wise solution
through the summit. The solution could be an answer in terms of
commercialization, regulatory policy or economy, or an answer
concerning the above two or more."
Li Hongjian, the founder, chairman, and CEO of Jiangsu Hillgene
Biopharma Co., Ltd., delivered the opening speech. "As a leading
professional CDMO company focused on cell therapy, since its
establishment, Hillgene Biopharma has exceeded a total service
order of over RMB 530 million, 100%
of which were for cell therapy projects (including 34 new drug
projects from academicians' teams), covering advanced therapies
such as CAR-T, CAR-NK, and TCR-T. We have successfully filed IND
for 8 projects, with 2 registered clinical projects underway.In
terms of international footprint, our company has supported 4
projects for FDA & EMA orphan drug designations. I hope this
1st CELL WORLD Global Cell Therapy Summit will further promote the
development and innovation of cell therapy industry globally and
provide more thoughts and practical examples."
Keynote Speeches
Dr. Fan Xiaohu, founder and CEO of Wondercel Biotech and former
Chief Scientist of Legend Biotech, gave an opening keynote report
titled "How Do Cell Therapy Products Participate in International
Competition".
Zhao Yuan, CTO of Jiangsu
Hillgene Biopharma Co., Ltd., expert of the European Medicines
Agency (EMA), and former Director of the Gene Therapy Division of
the Medicines and Healthcare Products Regulatory Agency (MHRA) in
the UK, shared strategies from the perspective of EU regulation on
the CMC of cell therapy drugs in her speech titled "CMC Strategy of
Cell Therapy Drug from the Perspective of EU Regulation".
Dr. He Xuhua, Director of the Department of Hematopathology at
Duke University School of Medicine and
Lifetime Professor of Hematologic Diagnosis at MD Anderson Cancer
Center in the US, delivered a report titled "Best Oncology Practice
for Implementation of CAR-T Therapy in DLBCL and Myeloma - From
Novel Data to Multidisciplinary Clinical Care".
Lv Xiaobin, a former senior review expert at the FDA and the
chief reviewer of CMC for Novartis' CAR-T drug Kymriah's BLA,
shared in his report "Viewing Cell Therapy Drug Registration in
the United States from a Review
Perspective," the challenges encountered during the drug
registration process, and how to combine different tools to
overcome these obstacles and gain approval smoothly.
Signing Ceremony for Strategic Cooperation
A signing ceremony for strategic cooperation was held
concurrently in this forum. Representatives of Jiangsu Hillgene
Biopharma Co., Ltd. successfully signed contracts with Shanghai NK
CellTech Co., Ltd., TCRx (Nanjing)
Therapeutics Co.Ltd, and Suzhou VDO Biotech Co., Ltd., to jointly
promote the efficient progress of cooperative projects and achieve
mutual benefits.
Round Table
Discussion
The round table discussion, themed "Cell Therapy Clinical
Research and Development Strategy Guided by Clinical Demand," was
hosted by Dr. Cai Xuejun, Vice President of Global R&D and Head
of China R&D Department at Bristol-Myers Squibb. Participants
included Dr. Zheng Xiaonan, Executive Vice Chairman and
Secretary-General of the China Biopharmaceutical Industry Chain
Innovation Transformation Alliance, Dr. Zhu Chouwen, Director of
Shanghai Clinical Research Center and President of Shanghai University of Science and Technology
Research Hospital, Dr. Zhou Huan,
Dean of the Clinical Trial Technology Academy of Anqing Medical
College and Director of the Clinical Trial Research Center of The
First Affiliated Hospital of Bengbu Medical College, Dr. Tian
Xiaopeng, Deputy Chief Physician of Hematology Department of the
First Affiliated Hospital of Soochow University, and Dr. Zhou
Jiawei, Research Doctor at the GCP Center of Cancer Hospital
Chinese Academy of Medical Sciences.
Executive Seminar
The executive seminar, themed "Cell Therapy Development Strategy
Aiming for International Success," was chaired by Dr. Zhang Dan. The attendees actively expressed
their opinions, having a thorough exchange and in-depth discussion
about the challenges in the field of cell therapy.
After the summit, all the attendees took a group photo for
memorabilia.
The "CELL WORLD 1st Global Cell Therapy Summit and Hillgene
Biopharma Anniversary Celebration" came to a perfect end amid the
laughter and joy of the banquet.
We thank all the participants, the organizers, and all the
behind-the-scenes staff for their hard work. Hillgene Biopharma
will continue to follow closely the development of the
biopharmaceutical field, always adhering to the vision of "letting
cell therapy write a new chapter of life," focusing on providing
cell therapy solutions for the industry, striving for perfection,
and committed to pushing more cell therapies to the market to
benefit more patients.
Hillgene Biopharma sincerely looks forward to moving ahead with
all the participants in the field of cell therapy, and hopes
to have more collaborations in the
industry to stride towards a bright and splendid future.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cell-world---aiming-at-internationalization-starting-from-regulation---the-1st-global-cell-therapy-summit-and-hillgene-biopharma-anniversary-celebration-successfully-held-301836480.html
SOURCE Hillgene